Asset Dedication LLC’s Insys Therapeutics, Inc. INSY Stock Holding History

Asset Dedication LLC’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100	Closed	–	–	658
2018 Q4	$0	Buy	+100	New	+$695	﹤0.01%	671

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Asset Dedication LLC's INSY Position: Q1 2019 in Review

Asset Dedication LLC sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 100 shares.

Asset Dedication LLC first reported a position in INSY in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Asset Dedication LLC reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Asset Dedication LLC sold 100 Insys Therapeutics, Inc. shares in Q1 2019.
Asset Dedication LLC first reported a position in Insys Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
Asset Dedication LLC's Insys Therapeutics, Inc. position peaked at $0 in Q4 2018.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Asset Dedication LLC's 13F filing for Q1 2019, filed 19 Apr 2019.